FDA NDA

PARIS, France, June 1, 2026 Abivax announced positive topline results from its pivotal Phase 3 ABTECT maintenance trial evaluating...

TAIPEI, Taiwan, May 27, 2026 Foresee Pharmaceuticals has announced the successful completion of its Casppian Phase 3 clinical trial...

FOSTER CITY, Calif., May 4, 2026 Mirum Pharmaceuticals, Inc. has announced that its Phase 2b VISTAS clinical study of...

Shanghai, China – April 22, 2026 In a major milestone for rare tumor therapeutics, Abbisko Therapeutics has announced significant...

Austin, Texas, USA, April 21, 2026 In a significant regulatory milestone for gastrointestinal therapeutics, Cristcot HD LLC has announced...

WALTHAM, Mass. and BOULDER, Colo., April 1, 2026 Cogent Biosciences, Inc. has announced the successful submission of a New...

RAHWAY, N.J. – October 15, 2025 — Merck (NYSE: MRK) announced new Phase 3 trial results for its investigational,...